He’s been arrested for securities fraud, resigned from the boards of at least two companies, been shredded by the punk bands whose label he bankrolled, and even faced calls to return the single existing copy of a Wu-Tang Clan record he paid $2 million for. KaloBios’s largest unsecured creditors include the University of Miami and Ernst and Young. Before the “boy wonder” CEO got his hands on KaloBios, the company sold a two-month treatment of benzidazole for $50-100. NASDAQ said that his arrest as well as the arrest of Evan Greebel, his outside counsel and a number of civil complaints which were filed against them by the SEC as well as his company’s failure for filing quarterly reports were the reasons why the notice had been sent.
Advertisement
At least 16 injured in huge Dubai hotel fire
The fireworks display went on for minutes as the crowd recorded and took pictures of the two skyscrapers. A huge fireworks display kicked off at the Burj Khalifa as smoke poured from the nearby hotel.
Martin Shkreli, the price-gouging pharmaceuticals CEO everyone loves to hate, may be the opposite of King Midas: Everything he touches shrivels and dies.
Facebook’s Free Basics service suspended in Egypt
Karthik Balakrishnan, a member of savetheinternet.in, agreed with Trai’s views that the issue was larger than just Free Basics . Authorities in Egypt effectively suspended the service when a required permit was not renewed after it lapsed on Wednesday.
On Monday, the company said that a couple of its board directors Marek Biestek and Tom Fernandez, resigned.
Sony Xperia Z6 Lite reportedly to come soon to the market
Some fans believe that Sony will announce the Sony Xperia Z6 at the CES 2016 but we will have to wait and see of that happens. The first flagship smartphone is said to launch in the month of June while the second device is presumed to come in October.
Turing raised the price on Daraprim, a 62-year-old drug whose patent expired decades ago, from $13.50 to $750 per pill.
The petition filed Tuesday in DE lists $8.37 million in assets and $1.94 million in debt, according to court papers.
The goal in the restructuring is allowing the company to focus its limited resources on development of lenzilumab its experimental drug for leukemia.
Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital…
The move comes shortly after the company appealed a decision by the Nasdaq stock market to delist its shares, Bloomberg Business reported.
Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011.
Advertisement
Shares at KaloBios surged from below $1 to more than $39 after Shkreli took over at KaloBios on November 20. The company’s stock has struggled in recent weeks after former CEO Martin Shkreli stepped down from the company amid allegations of stock manipulation. The company is asking for a court order to make sure it can hand out December 31 payroll checks to its eight remaining employees.
